Circulating tumor DNA tracking through driver mutations as a liquid biopsy-based biomarker for uveal melanoma.

We report, for the first time, compelling evidence from in vitro assays, and in vivo animal model and clinical specimens for the potential of mutated ctDNA as a biomarker of UM progression. These findings pave the way towards the implementation of a liquid biopsy to detect and monitor UM tumors.